From the perspective of providing a rapid and effective response to clinicians’ demands, a key strategy to address current limitations in CF treatment is theratyping—a precision medicine approach that uses preclinical testing to predict the responsiveness of rare and ultra-rare CFTR mutations to existing or novel CFTR modulators. The gene discussed is CFTR; the disease is cystic fibrosis.